Data Presentations News Today

Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior...

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights...

- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast... | May 9, 2023

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed...

Patients in Phase 3 ASCERTAIN study with biallelic TP53 mutations achieved median overall survival (mOS) of 13 months; mOS in the overall study po...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

- XPOVIO® (selinexor) approvals received in Mainland China, Australia, South Korea and Singapore, expect Hong Kong and Taiwan in remainder of 2022. - 2021 Revenue of RMB28.8 million, Named Patient Program paving way for strong commercial launch in 2022. - Broad and deep clinical program of 18 studies, including 5 registrational studies, ongoing across multiple regions. - Strong cash,...